PCN47 COMPARISON OF HEALTH CARE RESOURCE UTILIZATION AND COSTS BETWEEN NILOTINIB AND DASATINIB AS SECOND LINE THERAPIES IN CHRONIC MYELOID LEUKEMIA (CML)
Abstract
Authors
EQ Wu V Bollu A Guo A Guerin M Tsaneva D Williams JD Griffin